7 recruiting, 5 not yet recruiting, 4 unknown, 3 completed. 26 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 26 | Recruiting 7, Not yet recruiting 5, Unknown 4, Completed 3, Suspended 2, Terminated 2, Withdrawn 2, Active not recruiting 1 |
Follow Myositis: new trials by email Literature Review of Myositis trials Research Report on Myositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Not yet recruiting | Nanjing Bioheng Biotech Co., Ltd. | 30 | 2026-09-01 | 2026-07-16 |
| A Study of BEN301 Injection in theTreatment of Autoimmune Diseases Single administration of 1x10^8 viable CD4+ CAR+ Foxp3+ cells., Single administration of 3x10^8 viable CD4+ CAR+ Foxp3+ cells. - Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA) | Early Phase 1 | Suspended | RenJi Hospital | 24 | 2026-04-20 | 2026-06-04 |
| MTS109 in Patients With Refractory Autoimmune Diseases MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 15 | 2026-03-24 | 2026-06-30 |
| UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases UCAR-T cells - Systemic Lupus Erythematosus, Inflammatory Myopathy | Early Phase 1 | Withdrawn | The Affiliated Hospital of Xuzhou Medical University | 2026-03-01 | 2026-05-28 | |
| the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases V001-BCMA - Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases | Early Phase 1 | Active not recruiting | Tongji Hospital | 45 | 2025-11-04 | 2026-09-17 |
| GC012F Injection in Refractory Idiopathic Inflammatory Myopathy GC012F Injection infusion - Idiopathic Inflammatory Myopathy (IIM) | Early Phase 1 | Recruiting | Daishi Tian | 12 | 2025-09-15 | 2026-01-14 |
| An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases CD19/CD22/BCMA CAR-T cells(BZE2204) - Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP) | Early Phase 1 | Recruiting | Shanghai Cell Therapy Group Co.,Ltd | 20 | 2025-09-09 | 2026-11-12 |
| GC012F in Patients With Autoimmune Diseases GC012F injection - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM) | Early Phase 1 | Not yet recruiting | Qiong Fu | 15 | 2025-08-18 | 2025-07-18 |
| A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases LCAR-AIO T cells - Relapsed/Refractory Autoimmune Diseases | Early Phase 1 | Withdrawn | Nanjing Legend Biotech Co. | 2025-06-17 | 2025-07-08 | |
| Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV RD06-04 Cell Injection Infusion - Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis | Early Phase 1 | Not yet recruiting | Peking University People's Hospital | 12 | 2025-06-14 | 2025-05-22 |
| Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases UTAA91 injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Early Phase 1 | Not yet recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 15 | 2025-05-18 | 2025-05-14 |
| Safety Study of CC312 in Autoimmune Disease Patients CC312 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | Early Phase 1 | Recruiting | CytoCares Inc | 18 | 2024-11-08 | 2025-09-17 |
| Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 20 | 2024-09-14 | 2026-03-06 |
| Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases RD06-04 CART Cell Injection - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Suspended | Nanjing Bioheng Biotech Co., Ltd. | 12 | 2024-09-13 | 2026-02-03 |
| Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis Pozelimab/Cemdisiran - Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Austin Neuromuscular Center | 10 | 2024-08-08 | 2026-01-16 |
| IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy IMPT-514 CART Cell Injection - Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV) | Early Phase 1 | Terminated | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3 | 2024-06-13 | 2026-01-28 |
| The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 9 | 2024-05-27 | 2024-05-17 |
| Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases T cell injection targeting CD19 chimeric antigen receptor - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2024-05-14 | 2024-05-16 |
| Characterizing Myositis With 68Ga-FAPI PET/CT 68Ga-FAPI - Myositis, Idiopathic Inflammatory Myopathies | Early Phase 1 | Unknown | The First Affiliated Hospital of Xiamen University | 50 | 2023-07-01 | 2023-07-19 |
| Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases CD7 CAR T-cells - Crohn Disease, Ulcerative Colitis | Early Phase 1 | Unknown | Zhejiang University | 75 | 2022-02-28 | 2022-02-15 |
Showing 20 of 26. Sign in to see all of them.
Lupus Erythematosus, Systemic (14) · Scleroderma, Systemic (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9) · Autoimmune Diseases (7) · Sjogren's Syndrome (7) · Dermatomyositis (5) · Arthritis, Rheumatoid (4) · Purpura, Thrombocytopenic, Idiopathic (3) · Myositis, Inclusion Body (2) · Recurrence (2) · Anemia, Hemolytic, Autoimmune (1) · Antiphospholipid Syndrome (1) · Arthritis, Juvenile (1) · Autoimmune Diseases of the Nervous System (1)
Muscular Diseases (26) · Musculoskeletal Diseases (26) · Nervous System Diseases (26) · Neuromuscular Diseases (26) · Skin and Connective Tissue Diseases (21) · Connective Tissue Diseases (20) · Skin Diseases (19) · Immune System Diseases (18) · Autoimmune Diseases (11) · Arthritis (10) · Cardiovascular Diseases (10) · Joint Diseases (10) · Rheumatic Diseases (10) · Skin Diseases, Vascular (10) · Vascular Diseases (10)
68Ga-FAPI (1) · Abatacept (1) · Antigens, CD19 (1) · Cyclophosphamide (1) · Etanercept (1) · Fluid Therapy (1) · Hizentra (1) · Immunoglobulins (1) · Therapeutics (1) · fludarabine (1)
Nanjing Bioheng Biotech Co., Ltd. (3) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Tongji Hospital (2) · Austin Neuromuscular Center (1) · CytoCares Inc (1) · Daishi Tian (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Nanjing Legend Biotech Co. (1) · Peking University People's Hospital (1) · Pontificia Universidad Catolica de Chile (1) · Qiong Fu (1) · RenJi Hospital (1) · Shanghai Cell Therapy Group Co.,Ltd (1) · Shanghai Changzheng Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1)
China (19) · United States (4) · Chile (1)
Carl Pepine, MD (1) · Cristian Vera-Kellet, MD (1) · Glenn Lopate, MD (1) · Guixiu Shi, PhD (1) · He Huang, PhD (1) · Jian Wu, Doctor (1) · LI Sun, Master's (1) · Qiong Fu, Doctor (1) · Wei Wang, MD (1) · Yessar Hussain, MD (1)
PMID 19819109, PMID 24034070, PMID 32611669, PMID 37658205, PMID 40425008, PMID 41101309